Ovalbumin (154-159)
Need Assistance?
  • US & Canada:
    +
  • UK: +

Ovalbumin (154-159)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Ovalbumin (154-159) shows higher inhibition of the angiotensin-converting enzyme (ACE) at a concentration of 70 μM for 50% inhibition of ACE.

Category
Peptide Inhibitors
Catalog number
BAT-014815
CAS number
1370698-94-4
Molecular Formula
C28H52N10O9
Molecular Weight
672.78
IUPAC Name
(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[2-[[(2S)-4-amino-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
Synonyms
OVA (154-159); H-Thr-Asn-Gly-Ile-Ile-Arg-OH; Egg white albumen (154-159); L-threonyl-L-asparagyl-glycyl-L-isoleucyl-L-isoleucyl-L-arginine; H-TNGIIR-OH
Appearance
White Crystalline Solid
Purity
≥95%
Sequence
Thr-Asn-Gly-Ile-Ile-Arg
Storage
Store at -20°C
Solubility
Soluble in DMSO, Water
InChI
InChI=1S/C28H52N10O9/c1-6-13(3)21(37-19(41)12-34-23(42)17(11-18(29)40)36-24(43)20(30)15(5)39)26(45)38-22(14(4)7-2)25(44)35-16(27(46)47)9-8-10-33-28(31)32/h13-17,20-22,39H,6-12,30H2,1-5H3,(H2,29,40)(H,34,42)(H,35,44)(H,36,43)(H,37,41)(H,38,45)(H,46,47)(H4,31,32,33)/t13-,14-,15+,16-,17-,20-,21-,22-/m0/s1
InChI Key
ZGCUDFNQZIUUBG-CRFYWODOSA-N
Canonical SMILES
CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CCCN=C(N)N)C(=O)O)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C(C(C)O)N
1. [Effects of budesonide on airway inflammation and airway remodeling in the ovalbumin sensitized and challenged mice]
Hua-hao Shen, Shao-bin Wang Zhonghua Jie He He Hu Xi Za Zhi. 2005 Mar;28(3):154-9.
Objective: To investigate the effects of budesonide (BUD) used in an early phase or delayed phase on the airway inflammation and airway remodeling in ovalbumin (OVA) sensitized and challenged mice. Methods: Forty mice were divided into 5 groups (8 in each group) including group A [ovalbumin (OVA) sensitized/challenged mice], group B (saline sensitized/challenged mice), group C (OVA sensitized/challenged mice treated by BUD in the early phase), group D (OVA-sensitized/challenged mice treated by BUD in the late phase) and group E (OVA-sensitized/challenged mice following saline challenge for 18 days). Mice were sensitized on days 0 and 14 by OVA and challenged from days 24 to 41 by OVA repeatedly to establish a murine model of asthma characterized by airway inflammation and airway remodeling. To assess the effects of BUD on the development of airway remodeling and on established airway remodeling, animals were treated with aerosolized BUD (0.5 mg/ml per day) from day 1 before OVA challenge (group C) and from day 18 following first OVA challenge (group D). The outcome measurements included airway inflammatory indices, eosinophils (EOS) count and amount of collagen deposition around the bronchus, area of airway smooth muscle, the degree of mucus secretion in the lumens and depth of airway smooth muscle (ASM) in different grade bronchus by HE, PAS and Masson's staining. The bronchoalveolar lavage fluids (BALF) were assayed for IL-5 and IFN-gamma levels.
2. A model for the synthesis of glycoproteins
R J Ivatt Biosystems. 1975 Jul;7(1):154-9. doi: 10.1016/0303-2647(75)90053-2.
A technique is described for assaying membrane bound enzymes. The results of studies with two sequential glycoprotein:glycosyl transferases are presented. The results are discussed in the light of recent suggestions concerning the structural organisation of these enzymes. A description, of the specificity of these enzymes for high molecular weight substrates, is presented.
Online Inquiry
Verification code
Inquiry Basket